

[Home](#)

2. Ranibizumab

Ranibizumab (ophthalmic)

Generic name: ranibizumab (ophthalmic) [*RA-ni-BIZ-ue-mab-off-THAL-mik*]

Brand names: [Byooviz](#), [Cimerli](#), [Lucentis](#), [Susvimo](#), Susvimo Implant Kit

Dosage form: intravitreal solution (10 mg/mL; 100 mg/mL; 6 mg/mL; eqrn 10 mg/ml; eqrn 6 mg/ml; nuna 10 mg/mL)

Drug class: [Anti-angiogenic ophthalmic agents](#)



[Medically reviewed](#) by Drugs.com on Oct 31, 2023. Written by [Cerner Multum](#).

[Uses](#) [Side effects](#) [Warnings](#) [Before taking](#) [Dosage](#) [Interactions](#)

What is ranibizumab?

Ranibizumab ophthalmic (for the eyes) is used in adults to treat the "wet form" of age-related [macular degeneration](#). Ranibizumab is also used in adults to treat swelling in the retina caused by [diabetes](#), or a blockage in blood vessels.

Ranibizumab can also be used in adults to treat [diabetic retinopathy](#), and [myopia](#) caused by abnormal growth of new blood vessels in the retina.

Ranibizumab may also be used for purposes not listed in this medication guide.

Ranibizumab side effects

Get emergency medical help if you have **signs of an allergic reaction**: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Ranibizumab may cause serious side effects. Call your doctor at once if you have:

- increased eye pain, swelling, or redness in your eye;
- vision loss, sensitivity to light;
- blurred vision, seeing halos around lights;
- feeling like something is in your eye;
- discharge or watery eyes;
- sudden changes in your vision, seeing flashes of light; or
- a "spider webs" appearance in your vision.

Common side effects of ranibizumab may include:

- eye pain;

- sensitivity to light;
- "floaters" in your vision;
- increased pressure inside the eye; or
- [eye redness](#) or a blood spot on the white of your eye.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

 [Ranibizumab ophthalmic side effects](#) (more detail)

Related/similar drugs

Syfovre

Syfovre (pegcetacoplan) treatment for geographic atrophy (GA) a form of dry age-related macular ...

Reviews & ratings

[6 Reviews](#)

[View more](#)

Eylea

Eylea is used to treat several retinal disorders, such as neovascular (wet) age-related macular ...

Reviews & ratings

7.1 / 10

[70 Reviews](#)

[View more](#)

FEATURED

Izervay

Izervay (avacincaptad pegol) is used for treating geographic atrophy (GA) due to age-related ...

Reviews & ratings

[3 Reviews](#)

[View more](#)

Vabysmo

Vabysmo eye injection is used to treat eye diseases neovascular (wet) age-

eye diseases neovascular (wet) age-related macular ...

Reviews & ratings

7.8 / 10

[30 Reviews](#)

[View more](#)

Ozurdex

Ozurdex is an implant injected into the eye to treat swelling that may occur when there is a ...

Reviews & ratings

6.1 / 10

[8 Reviews](#)

[View more](#)

Lucentis

Lucentis is used to treat the wet form of age-related macular degeneration. Learn about side ...

Reviews & ratings

6.1 / 10

[15 Reviews](#)

[View more](#)

Aflibercept ophthalmic

Aflibercept is an injectable eye preparation that may be given by a healthcare provider every one ...

Reviews & ratings

6.9 / 10

[77 Reviews](#)

[View more](#)

Warnings

You should not receive ranibizumab if you have swelling, redness, pain inside your eyes, or any type of [infection](#) in or around your eyes.

Call your doctor at once if you have sudden vision problems, eye pain, redness, discharge, or watering in your eye, or if your eyes are more sensitive to light.

Before taking this medicine

You should not receive ranibizumab if you are allergic to it, or if you have:

- swelling, redness, pain inside or around your eyes; or
- any type of infection in or around your eyes.

Tell your doctor if you have or have ever had:

- an eye infection;
- retinal detachment;
- a [heart attack](#), or [stroke](#);
- [glaucoma](#) or other condition that increases pressure inside your eyes; or
- taken certain other medicines that can increase bleeding risk such as [warfarin](#), [aspirin](#), or [nonsteroidal anti-inflammatory drugs](#) (NSAID).

It is not known if ranibizumab will harm an unborn baby. Use effective [birth control](#) while using ranibizumab and for at least 12 months after your last dose. Tell your doctor if you are pregnant or plan to become pregnant.

Ask a doctor if it is safe to breastfeed while using ranibizumab.

How is ranibizumab given?

Follow all directions on your prescription label and read all medication guides or instruction sheets.

Ranibizumab **injection** is administered as an injection into the eye. Your doctor will use a medicine to numb your eye before giving you the injection. You will receive this injection in your doctor's office or other clinical setting.

Ranibizumab **eye implant** is placed through the white part of the eye by your healthcare provider who will refill your implant once every 6 months.

If you have a ranibizumab **eye implant**, talk to your doctor if you have an appointment for an MRI (magnetic resonance imaging).

Your eyes will be checked to make sure ranibizumab has not caused any serious side effects.

Call your doctor right away if you notice the **eye implant** has moved out of place.

Wash your hands first if you have to rub your eyes or touch the area where the **eye implant** is located.

Ranibizumab dosing information

Usual Adult Dose for Macular Degeneration:

0.5 mg via intravitreal injection once a month (approximately 28 days)

Use: Neovascular (wet) age-related macular degeneration (AMD)

Usual Adult Dose for Diabetic Retinopathy:

-DME and Diabetic [Retinopathy](#) with DME:

0.3 mg via intravitreal injection once a month (approximately 28 days)

-[Macular Edema](#) following RVO:

0.5 mg via intravitreal injection once a month (approximately 28 days)

Uses: [Diabetic macular edema](#) (DME); diabetic retinopathy with DME; macular edema following retinal vein occlusion (RVO)

Usual Adult Dose for Macular Edema:

-DME and Diabetic Retinopathy with DME:

0.3 mg via intravitreal injection once a month (approximately 28 days)

-Macular Edema following RVO:

0.5 mg via intravitreal injection once a month (approximately 28 days)

Uses: Diabetic macular edema (DME); diabetic retinopathy with DME; macular edema following retinal vein occlusion (RVO)

 [Detailed Ranibizumab ophthalmic dosage information](#)

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your ranibizumab injection.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid after receiving ranibizumab?

Avoid driving or hazardous activity until the eye shield can be removed and you are able to see clearly.

What other drugs will affect ranibizumab?

Medicine used in the eyes is not likely to be affected by other drugs you use. But many drugs can interact. Tell your doctor about all your current medicines, including prescription and over-the-counter medicines, [vitamins](#), and [herbal products](#).

 [Ranibizumab ophthalmic drug interactions](#) (more detail)

Does ranibizumab ophthalmic interact with my other drugs?

Enter medications to view a detailed interaction report using our [Drug Interaction Checker](#).

ranibizumab ophthalmic

+

Enter a drug name

Add

Ranibizumab ophthalmic Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There are 2 for ranibizumab ophthalmic.

Lucentis (ranibizumab) - Genentech, Inc.

▼

Formulation type	Strength
Pre-Filled Syringe	10 mg/mL (0.5 mg/0.05 mL)
Pre-Filled Syringe	6 mg/mL (0.3 mg/0.05 mL)
Single-Dose Vial	10 mg/mL (0.5 mg/0.05 mL)
Single-Dose Vial	6 mg/mL (0.3 mg/0.05 mL)

View [Lucentis](#) information in detail.

Susvimo (ranibizumab) - Genentech, Inc.

▼

Lucentis interchangeable products

Interchangeable biosimilar products can be dispensed by a pharmacist without the intervention of the prescriber of the reference product.

Pharmacy laws for biosimilar prescribing may vary by state.

Byooviz (ranibizumab-nuna) - Samsung Bioepis Co., Ltd.

▼

Cimerli (ranibizumab-eqrn) - Sandoz Inc.

▼

More about ranibizumab ophthalmic

- [Check interactions](#)
- [Compare alternatives](#)
- [Reviews \(18\)](#)
- [Side effects](#)
- [Dosage information](#)
- [During pregnancy](#)
- [Drug class: anti-angiogenic ophthalmic agents](#)
- [Breastfeeding](#)

Patient resources

- [Ranibizumab advanced reading](#)
- [Ranibizumab-eqrn \(Advanced Reading\)](#)
- [Ranibizumab](#)

Other brands

[Lucentis](#), [Byooviz](#), [Cimerli](#), [Susvimo](#)

Professional resources

- [Ranibizumab monograph](#)

Other brands

[Lucentis](#), [Byooviz](#), [Cimerli](#), [Susvimo](#)

Related treatment guides

- [Myopic Choroidal Neovascularization](#)
- [Diabetic Macular Edema](#)
- [Diabetic Retinopathy](#)
- [Macular Degeneration](#)

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

[Medical Disclaimer](#)

DRUG STATUS

Availability

Rx Prescription only

Pregnancy & Lactation

 Risk data available

CSA Schedule*

N/A Not a controlled drug



User Reviews & Ratings

6.6 / 10

[18 Reviews](#)

Related News

[FDA Approves Genentech's Susvimo as the First and Only Continuous Delivery Treatment for the Treatment of Diabetic Macular Edema](#)

Images

[Lucentis \(ranibizumab\) 0.5 mg/0.05 mL \(10 mg/mL\) prefilled syringe](#)



[View larger images](#)

Drugs.com Mobile App

Access drug & treatment information, identify pills, check interactions and set up personal medication records.



About

[About Drugs.com](#)

[Advertising policy](#)

[Attribution & citations](#)

Terms & privacy

[Terms of use](#)

[Editorial policy](#)

[Privacy policy](#)

Support

[Help center](#)

[Sitemap](#)

[Contact us](#)



[Subscribe to our newsletter](#) for the latest medication news, new drug approvals and FDA alerts.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated 7 Apr 2025), Cerner Multum™ (updated 13 Apr 2025), ASHP (updated 10 Apr 2025) and others.



Copyright © 2000-2025 Drugs.com. All rights reserved.

